Cover Image
市場調查報告書

特發性(原發性)高血壓 : 開發平台分析

Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251558
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
特發性(原發性)高血壓 : 開發平台分析 Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 62 Pages
簡介

原發性高血壓又稱之為特發性高血壓,定義是沒有特定原因造成的高血壓之一種型態。原發性高血壓隨著老年化而增加,但年輕人若血壓相對較高,高血壓的發病風險也高。高血壓會提升大腦、心臟、腎臟相關事故的風險。發病的原因有遺傳因素,年齡,運動不足和高脂肪食,鹽分的過度攝取等生活習慣。由於肥胖及運動不足的增加,預測高血壓今後仍將持續增加。

本報告提供特發性(原發性)高血壓的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新新聞及發表。

簡介

  • 調查範圍

特發性(原發性)高血壓 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Bayer AG
  • Chong Kun Dang Pharmaceutical Corp.
  • Eli Lilly and Company
  • HanAll Biopharma Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lee's Pharmaceutical Holdings Limited
  • PhaseBio Pharmaceuticals, Inc.
  • Quantum Genomics SA
  • Sun Pharma Advanced Research Company Ltd.
  • Takeda Pharmaceutical Company Limited
  • TSH Biopharm Corporation Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)
  • (amlodipine besylate + candesartan cilexetil)
  • (amlodipine besylate + hydrochlorothiazide + losartan potassium)
  • (atorvastatin calcium + losartan potassium)
  • (nifedipine + candesartan cilexetil)
  • azilsartan medoxomil
  • carvedilol phosphate ER
  • carvedilol phosphate SR
  • CRTA-04
  • LY-2623091
  • PB-1046
  • PB-1120
  • QGC-001
  • rostafuroxin

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8388IDB

Summary

Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016', provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
  • The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic (Essential) Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic (Essential) Hypertension - Overview
  • Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies
  • Idiopathic (Essential) Hypertension - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Idiopathic (Essential) Hypertension - Products under Development by Companies
  • Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Bayer AG
    • Chong Kun Dang Pharmaceutical Corp.
    • Daiichi Sankyo Company, Limited
    • Eli Lilly and Company
    • HanAll Biopharma Co., Ltd.
    • Innopharmax Inc.
    • Lee's Pharmaceutical Holdings Limited
    • PhaseBio Pharmaceuticals, Inc.
    • Quantum Genomics SA
    • Takeda Pharmaceutical Company Limited
  • Idiopathic (Essential) Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (amlodipine besylate + candesartan cilexetil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + losartan potassium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (candesartan cilexetil + nifedipine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azilsartan medoxomil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carvedilol phosphate CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lisinopril - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2623091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-1046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-1120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QGC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rostafuroxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Idiopathic (Essential) Hypertension - Dormant Projects
  • Idiopathic (Essential) Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure
      • Jun 12, 2013: Lee's Pharma Enrolls First Patient in Phase IIb Clinical Trial of Rostafuroxin in Italy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H2 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Idiopathic (Essential) Hypertension - Dormant Projects, H2 2016
  • Idiopathic (Essential) Hypertension - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top